Related Experiment Video
Updated: Mar 19, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Identifying Consistent High-cost Users in a Health Plan: Comparison of Alternative Prediction Models
Hsien-Yen Chang1, Cynthia M Boyd, Bruce Leff
1*Department of Health Policy & Management †Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health ‡Department of Medicine, Division of Geriatric Medicine and Gerontology, School of Medicine, Johns Hopkins University §Center for Population Health Information Technology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Background:
High-cost users in a period may not incur high-cost utilization in the next period. Consistent high-cost users (CHUs) may be better targets for cost-saving interventions.
Objectives:
To compare the characteristics of CHUs (patients with plan-specific top 20% medical costs in all 4 half-year periods across 2008 and 2009) and point high-cost users (PHUs) (top users in 2008 alone), and to build claims-based models to identify CHUs.
Research Design:
This is a retrospective cohort study. Logistic regression was used to predict being CHUs. Independent variables were derived from 2007 claims; 5 models with different sets of independent variables (prior costs, medications, diagnoses, medications and diagnoses, medications and diagnoses and prior costs) were constructed.
Subjects:
Three-year continuous enrollees aged from 18 to 62 years old from a large administrative database with $100 or more yearly costs (N=1,721,992).
Measures:
Correlation, overlap, and characteristics of top risk scorers derived from 5 CHUs models were presented. C-statistics, sensitivity, and positive predictive value were calculated.
Results:
CHUs were characterized by having increasing total and pharmacy costs over 2007-2009, and more baseline chronic and psychosocial conditions than PHUs. Individuals' risk scores derived from CHUs models were moderately correlated (∼0.6). The medication-only model performed better than the diagnosis-only model and the prior-cost model.
Conclusions:
Five models identified different individuals as potential CHUs. The recurrent medication utilization and a high prevalence of chronic and psychosocial conditions are important in differentiating CHUs from PHUs. For cost-saving interventions with long-term impacts or focusing on medication, CHUs may be better targets.
More Related Videos
Related Concept Videos
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Comparing the Survival Analysis of Two or More Groups
Prediction Intervals
However, the point estimate is most likely not the exact value of the population parameter, but close to it. After calculating point estimates, we construct interval estimates, called confidence intervals or prediction intervals. This prediction interval comprises a range of values unlike the point estimate and is a better predictor of the observed sample value, y.
Analysis of Population Pharmacokinetic Data
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...

